Drugs / HSC835
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02715505 | Oct 2017 → May 2020 | inborn errors of metabolism | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01474681 | Jan 2012 → Oct 2016 | Burkitt lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +6 | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03674411 | Jan 2019 → Jun 2020 overdue | Burkitt lymphoma, Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, acute biphenotypic leukemia +5 | Masonic Cancer Center, University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03406962 | Feb 2018 → Feb 2020 | inborn errors of metabolism | Magenta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01930162 | Oct 2014 → Aug 2016 | chronic lymphocytic leukemia/small lymphocytic lymphoma, myelodysplastic syndrome, plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSC835 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01474681 ↗ |
| Known as | MGTA 456 | “Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy” NCT03674411 ↗ |
| Modality | Cell therapy | “LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells” NCT01474681 ↗ |
| Route | Other | “MGTA 456 Infusion” NCT03674411 ↗ |